SeekingAlpha · Nov 11, 2025
FibroGen, Inc. 2025 Q3 - Results - Earnings Call Presentation
2025-11-11. The following slide deck was published by FibroGen, Inc.
FG
NASDAQ · FGEN
FibroGen, Inc.
Healthcare · Biotechnology
$9.07
Down-$0.15 (-1.63%)
Updated Oct 27, 2026, 8:11 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 35.36M
- P/E ratio
- -17.1
- Dividend yield
- 0.00%
- 52-week range
- $4.85 – $12.60
- Volume
- 34.23K
- Avg. volume
- 30.11K
Price performance · FGEN
FGEN price history
1M range · 0 trading sessions · Daily adjusted prices
FGEN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest FGEN news
The latest Smart Investors Daily articles mentioning FGEN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
FGEN research
Overview
Company profile and research snapshot.
Company profile
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.00
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2025 | HC Wainwright & Co. | Buy | — |
| May 13, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 18, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 20, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 11, 2025
FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ...
FibroGen Inc (FGEN) reports significant cost reductions and a strengthened cash position following the sale of FibroGen China, while navigating potential risks in ongoing trials.
Yahoo · Nov 10, 2025
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of +59.85% and -34.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
SeekingAlpha · Nov 10, 2025
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call November 10, 2025 5:00 PM ESTCompany ParticipantsThane Wettig - CEO & DirectorDavid DeLucia - Senior VP...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
